Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice

Journal of Experimental Medicine

Volumn 204, Issue 3, 2007, Pages 657-666

  Jiang, Youchun ^a   Reynolds, Corey ^a   Xiao, Chang ^a   Feng, Wenke ^a   Zhou, Zhanxiang ^a   Rodriguez, Walter ^a   Tyagi, Suresh C ^a   Eaton, John W ^a   Saari, Jack T ^b   Kang, Y James ^a  

^a University of Louisville School of Medicine   (United States)

^b US Department of Agriculture Human Nutrition Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE SILENCING; HEART FAILURE; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; CHRONIC DISEASE; COPPER; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL;

EID: 33947359043     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061943     Document Type: Article

References (35)

1. Klevay, L.M. 2000. Cardiovascular disease from copper deficiency - a history. J. Nutr. 130:489s-492s.
2. Trumbo, P., A.A. Yates, S. Schlicker, and M. Poos. 2001. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet. Assoc. 101:294-301.
3. Klevay, L.M., and D.M. Medeiros. 1996. Deliberations and evaluations of the approaches, endpoints and paradigms for dietary recommendations about copper. J. Nutr. 126:S2419-S2426.
4. Reiser, S., J.C. Smith Jr., W. Mertz, J.T. Holbrook, D.J. Scholfield, A.S. Powell, W.K. Canfield, and J.J. Canary. 1985. Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am. J. Clin. Nutr. 42:242-251.
5. Wester, P.O. 1965. Trace elements in human myocardial infarction determined by neutron activation analysis. Acta Med. Scand. 178:765-788.
6. Zama, N., and R.L.R. Towns. 1986. Cardiac copper, magnesium, and zinc in recent and old myocardial infarction. Biol. Trace Elem. Res. 10:201-208.
7. Anderson, T.W., L.C. Neri, G.B. Schreiber, F.D.F. Talbot, and A. Zdrojewski. 1975. Ischemic heart disease, water hardness and myocardial magnesium. Can. Med. Assoc. J. 113:199-203.
8. Chipperfield, B., and J.R. Chipperfield. 1978. Differences in metal content of the heart muscle in death from ischemic heart disease. Am. Heart J. 95:732-737.
9. Papadopoulou, L.C., C.M. Sue, M.M. Davidson, K. Tanji, I. Nishino, J.E. Sadlock, S. Krishna, W. Walker, J. Selby, D.M. Glerum, et al. 1999. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat. Genet. 23:333-337.
10. Freisinger, P., R. Horvath, C. Macmillan, J. Peters, and M. Jaksch. 2004. Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper? J. Inherit. Metab. Dis. 27:67-79.
11. Witte, K.K.A., N.P. Nikitin, A.C. Parker, S. von Haehling, H.D. Volk, S.D. Anker, A.L. Clark, and J.G.F. Cleland. 2005. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur. Heart J. 26:2238-2244.
12. Shiojima, I., K. Sato, Y. Izumiya, S. Schiekofer, M. Ito, R.L. Liao, W.S. Colucci, and K. Walsh. 2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115:2108-2118.
13. Izumiya, Y., I. Shiojima, K. Sato, D.B. Sawyer, W.S. Colucci, and K. Walsh. 2006. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 47:887-893.
14. Takimoto, E., H.C. Champion, M.X. Li, D. Belardi, S.X. Ren, E.R. Rodriguez, D. Bedja, K.L. Gabrielson, Y.B. Wang, and D.A. Kass. 2005. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11:214-222.
15. Klevay, L.M., J.P. Buchet, V.W. Bunker, B.E. Clayton, R.S. Gibson, D.M. Medeiros, P.B. Moser-Veillon, K.Y.T.L.J. Patterson, and W.R. Wolf. 1993. Copper in the western diet (Belgium, Canada, U.K. and USA). In Trace elements in man and animals-TEMA 8. M. Anke, D. Meissner, and C.F. Mills, editors). Verlag media touristik, Gersdorf, Germany. 207-210.
16. Pang, Y., D.L. MacIntosh, and P.B. Ryant. 2001. A longitudinal investigation of aggregate oral intake of copper. J. Nutr. 131:2171-2176.
17. Hunt, C.D., and S.L. Meacham. 2001. Aluminum, boron, calcium, copper, iron, magnesium, manganese, molybdenum, phosphorus, potassium, sodium, and zinc: concentrations in common Western foods and estimated daily intakes by infants; toddlers; and male and female adolescents, adults, and seniors in the United States. J. Am. Diet. Assoc. 101:1058-1060.
18. Pan, Q., C.G. Kleer, K.L. van Golen, J. Irani, K.M. Bottema, C. Bias, M. De Carvalho, E.A. Mesri, D.M. Robins, R.D. Dick, et al. 2002. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62:4854-4859.
19. Ziche, M., J. Jones, and P.M. Gullino. 1982. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:475-482.
20. Mandinov, L., A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, V. Kolev, R. Soldi, C. Bagala, E. D.de Muinck, V. Lindner, et al. 2003. Copper chelation represses the vascular response to injury. Proc. Natl. Acad. Sci. USA. 100:6700-6705.
21. Tapiero, H., D.M. Townsend, and K.D. Tew. 2003. Trace elements in human physiology and pathology. Copper. Biomed. Pharmacother. 57:386-398.
22. Elsherif, L., Y. Jiang, J.T. Saari, and Y.J. Kang. 2004. Dietary copper restriction-induced changes in myocardial gene expression and the effect of copper repletion. Exp. Biol. Med. (Maywood). 229:616-622.
23. Sen, C.K., S. Khanna, M. Venojarvi, P. Trikha, E.C. Ellison, T.K. Hunt, and S. Roy. 2002. Copper-induced vascular endothelial growth factor expression and wound healing. Am. J. Physiol. Heart Circ. Physiol. 282:H1821-H1827.
24. Elsherif, L., L.P. Wang, J.T. Saari, and Y.J. Kang. 2004. Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice. J. Nutr. 134:855-860.
25. Rae, T.D., P.J. Schmidt, R.A. Pufahl, V.C. Culotta, and T.V. O'Halloran. 1999. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science. 284:805-808.
26. Culotta, V.C., L.W.J. Klomp, J. Strain, R.L.B. Casareno, B. Krems, and J.D. Gitlin. 1997. The copper chaperone for superoxide dismutase. J. Biol. Chem. 272:23469-23472.
27. Reeves, P.G., F.H. Nielsen, and G.C. Fahey. 1993. Ain-93 purified diets for laboratory rodents - final report of the American Institute of Nutrition Ad Hoc Writing Committee on the reformulation of the Ain-76A rodent diet. J. Nutr. 123:1939-1951.
28. Ding, B., R.L. Price, T.K. Borg, E.O. Weinberg, P.F. Halloran, and B.H. Lorell. 1999. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ. Res. 84:729-734.
29. Shioi, T., J.R. McMullen, O. Tarnavski, K. Converso, M.C. Sherwood, W.J. Manning, and S. Izumo. 2003. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 107:1664-1670.
30. McMullen, J.R., M.C. Sherwood, O. Tarnavski, L. Zhang, A.L. Dorfman, T. Shioi, and S. Izumo. 2004. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 109:3050-3055.
31. Chen, Y., J.T. Saari, and Y.J. Kang. 1994. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic. Biol. Med. 17:529-536.
32. Kang, Y.J., Y. Chen, A. Yu, M. Voss-McCowan, and P.N. Epstein. 1997. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 100:1501-1506.
33. Campian, J.L., M. Qian, X. Gao, and J.W. Eaton. 2004. Oxygen tolerance and coupling of mitochondrial electron transport. J. Biol. Chem. 279:46580-46587.
34. Feng, W., J. Cai, W.M. Pierce, R.B. Franklin, W. Maret, F.W. Benz, and Y.J. Kang. 2005. Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts. Biochem. Biophys. Res. Commun. 332:853-858.
35. Wang, G.W., J.B. Klein, and Y.J. Kang. 2001. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J. Pharmacol. Exp. Ther. 298:461-468.